Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Huiyul Park¹, Eileen L Yoon², Seon Cho³, Eun-Hee Nah⁴, Dae Won Jun⁵

Affiliations

¹ Department of Family Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Republic of Korea.
² Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Republic of Korea.
³ Department of Laboratory Medicine, Health Promotion Research Institute, Seoul, Republic of Korea.
⁴ Department of Laboratory Medicine, Health Promotion Research Institute, Seoul, Republic of Korea. Electronic address: cellonah@hanmail.net.
⁵ Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Republic of Korea. Electronic address: noshin@hanyang.ac.kr.

PMID: 34116080
DOI: 10.1016/j.jhep.2021.05.035

Comment

Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Huiyul Park et al. J Hepatol. 2021 Sep.

. 2021 Sep;75(3):725-726.

doi: 10.1016/j.jhep.2021.05.035. Epub 2021 Jun 9.

Authors

Huiyul Park¹, Eileen L Yoon², Seon Cho³, Eun-Hee Nah⁴, Dae Won Jun⁵

Affiliations

¹ Department of Family Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Republic of Korea.
² Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Republic of Korea.
³ Department of Laboratory Medicine, Health Promotion Research Institute, Seoul, Republic of Korea.
⁴ Department of Laboratory Medicine, Health Promotion Research Institute, Seoul, Republic of Korea. Electronic address: cellonah@hanmail.net.
⁵ Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Republic of Korea. Electronic address: noshin@hanyang.ac.kr.

PMID: 34116080
DOI: 10.1016/j.jhep.2021.05.035

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment on

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, Tsochatzis EA, Rosenberg W. Srivastava A, et al. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6. J Hepatol. 2019. PMID: 30965069
FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
Wu Y, Kumar R, Huang J, Wang M, Zhu Y, Lin S. Wu Y, et al. J Hepatol. 2021 Jan;74(1):247-248. doi: 10.1016/j.jhep.2020.06.040. Epub 2020 Sep 29. J Hepatol. 2021. PMID: 32994079 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Affiliations

Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical